» Articles » PMID: 9680360

Exclusion of the First EGF Domain of Factor VII by a Splice Site Mutation Causes Lethal Factor VII Deficiency

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1998 Jul 29
PMID 9680360
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

We have studied a family with homozygous lethal, blood coagulation factor VII (FVII) deficiency. To identify the mutation responsible for the deficiency, exons 2 to 8 and the intron-exon junctions of their FVII genes were amplified from peripheral white blood cell DNA by polymerase chain reaction and screened by single-strand conformational polymorphism analysis. The fragment showing aberrant mobility was cloned and sequenced. We detected a single point mutation, a homozygous G to A substitution at nucleotide position 6070, in the invariant GT dinucleotide at the 5' splice site of intron 4. Homozygosity was confirmed by loss of a site for the restriction endonuclease Mlu I. Analysis of the splicing pattern of ectopic transcripts in lymphocytes in the parents revealed that this mutation is associated with skipping of exon 4, which produces an mRNA encoding FVII with an in-frame deletion of the first epidermal growth factor-like domain (EGF 1). Transient transfection of COS-7 cells with an expression vector containing the triangle upEGF 1 FVII cDNA shows that this mutant protein is not expressed. The identification of the molecular basis of the FVII deficiency in this family allowed mutation-specific prenatal diagnosis to be performed in a subsequent pregnancy. In this family complete FVII deficiency is associated with a severe bleeding diathesis but no developmental abnormalities, lending weight to the hypothesis that fetal FVII is not required for the putative angiogenic functions of tissue factor in humans.

Citing Articles

Hereditary coagulation factor VII deficiency caused by novel compound heterozygous mutations in a Chinese pedigree: A case report.

Cai R, Li Y, Xu W, Gao X, Feng Q J Clin Lab Anal. 2022; 37(1):e24768.

PMID: 36572978 PMC: 9833959. DOI: 10.1002/jcla.24768.


Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis.

Bernardi F, Mariani G Haematologica. 2021; 106(2):351-362.

PMID: 33406812 PMC: 7849579. DOI: 10.3324/haematol.2020.248542.


Unraveling the effect of silent, intronic and missense mutations on splicing: contribution of next generation sequencing in the study of mRNA.

Borras N, Orriols G, Batlle J, Perez-Rodriguez A, Fidalgo T, Martinho P Haematologica. 2018; 104(3):587-598.

PMID: 30361419 PMC: 6395343. DOI: 10.3324/haematol.2018.203166.


Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant.

Cavallari N, Balestra D, Branchini A, Maestri I, Chuamsunrit A, Sasanakul W Biochim Biophys Acta. 2012; 1822(7):1109-13.

PMID: 22426302 PMC: 3787739. DOI: 10.1016/j.bbadis.2012.03.001.


Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.

Margaritis P, Arruda V, Aljamali M, Camire R, Schlachterman A, High K J Clin Invest. 2004; 113(7):1025-31.

PMID: 15057309 PMC: 379321. DOI: 10.1172/JCI20106.